Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings by M.C. Maggio et al.
CASE REPORT Open Access
Kawasaki disease triggered by parvovirus
infection: an atypical case report of two
siblings
M. C. Maggio1*, R. Cimaz2,3, A. Alaimo4, C. Comparato4, D. Di Lisi4 and G. Corsello1
Abstract
Background: There are reports of the familial occurrence of Kawasaki disease but only a few reports described
Kawasaki disease in siblings. However, the familial cases were not simultaneous. In these patients the idea of
infective agents as trigger must be considered.
Case presentation: We describe two siblings with atypical presentations of Kawasaki disease; the sister was first
diagnosed as having parvovirus infection with anemia and the brother was diagnosed as having myocarditis.
The first patient was a 9-month-old Caucasian girl with fever, conjunctivitis, rash, and pharyngitis, and later she had
cervical adenopathy, diarrhea and vomiting, leukocytosis, and anemia, which were explained by positive
immunoglobulin M against parvovirus. However, coronary artery lesions with aneurysms were documented at day
26 after fever onset. An infusion of intravenous immunoglobulin and high doses of steroids were not efficacious to
resolve the coronary lesions. She was treated with anakinra, despite a laboratory test not showing inflammation,
with prompt and progressive improvement of coronary lesions.
Her 7-year-old Caucasian brother presented vomiting and fever at the same time as she was unwell, which
spontaneously resolved after 4 days. Four days later, he again presented with fever with abdominal pain, associated with
tachypnea, stasis at the pulmonary bases, tachycardia, gallop rhythm, hypotension, secondary anuria, and hepatomegaly.
An echocardiogram revealed a severe hypokinesia, with a severe reduction of the ejection fraction (20%).
He had an increase of immunoglobulin M anti-parvovirus, tested for the index case of his sister, confirming the suspicion
of viral myocarditis. He received dopamine, dobutamine, furosemide plus steroids, with a progressive increase of the
ejection fraction to 50%. However, evaluating his sister’s history, the brother showed a myocardial dysfunction secondary
to Kawasaki shock syndrome.
Conclusions: We report on familial Kawasaki disease in two siblings which had the same infectious trigger (a
documented parvovirus infection). The brother was diagnosed as having post-viral myocarditis. However, in view of the
two different and simultaneous evolutions, the girl showed Kawasaki disease with late coronary artery lesions and
aneurysms, whereas the brother showed Kawasaki shock syndrome with myocardial dysfunction.
We stress the effectiveness of anakinra in non-responder Kawasaki disease and the efficacy on coronary aneurysms.
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Background
There are reports of the familial occurrence of Kawasaki
disease (KD) but only a few reports described KD in sib-
lings [1]. However, the familial cases were reported at
different times, not simultaneously. Epidemiological
studies indicated that specific viral and/or bacterial in-
fections and an underlying genetics may trigger KD. Fur-
thermore, the detection of a specific infectious agent,
which could explain the clinical course of atypical or in-
complete KD, may delay the correct diagnosis, with an
increased risk of coronary artery lesions (CAL).
Treatment with intravenous immunoglobulin (IVIG) is
useful if started within 10 days from the beginning of
fever. When a delay is due to incomplete and/or atypical
KD, an increased risk of CAL is reported [2].
In non-responders, with a severe outcome and/or high
risk of CAL, a more aggressive treatment must be con-
sidered, with high doses of steroids, anti-interleukin
(IL)-1 biologic drugs, and immune suppressive drugs [3].
Anakinra, a recombinant antagonist of IL-1 receptor,
inhibits binding of IL-1 alpha and beta with the receptor
and, in this way, down-regulates IL-1-mediated inflam-
mation. KD, considered an autoinflammatory disease,
recognizes in IL-1 the therapeutic target to blockade sys-
temic symptoms and CAL [4].
We report the clinical cases of a brother and sister
who were admitted to two different units of our Chil-
dren Hospital with a late diagnosis of severe KD, in
whom parvovirus infection seemed to be the probable
triggering factor.
Case presentation
Case number 1
A 9-month-old Caucasian girl presented to our pediatric
unit with fever, pallor, bilateral non-secreting conjunctiv-
itis, and rash. Anamnestic records revealed that 12 days
before she had remittent fever, which spontaneously re-
solved in 5 days. Fever started again after 3 days, associ-
ated with pharyngitis, and, later, with cervical adenopathy,
diarrhea, and vomiting. She was treated with amoxicillin
plus clavulanic acid and steroids, without defervescence.
At admission, 9 days after fever onset, she showed fever,
conjunctivitis, pharyngitis, generalized rash, and bilateral
cervical adenopathy. Hematological parameters revealed:
leukocytes, 18,000/mm3 with neutrophils of 8520/mm3,
lymphocytes of 6250/mm3, and monocytes of 1930/mm3;
hemoglobin, 9.1 g/dl; platelets, 318,000/mm3; and trans-
aminases, albumin, natremia, and urine analysis in the
normal range. Her C-reactive protein (CRP) was 2.31mg/
dl; her erythrocyte sedimentation rate (ESR) was 120.
An electrocardiogram (ECG) and echocardiography
were normal, including coronary Z-scores. IgM and IgG
against Epstein–Barr virus, cytomegalovirus, and parvo-
virus were tested, and she showed positive IgM against
parvovirus. This was confirmed at further testing after
10 days. She was treated with clarithromycin and ob-
tained quick defervescence. A diagnosis of parvovirus in-
fection with severe anemia was made. For this reason
and because of the prompt defervescence, it was exclu-
sively treated as a viral infection. During follow-up, fur-
ther cardiologic evaluation was done because of the risk
of pericarditis secondary to the parvovirus infection, and
at day 26 after fever onset, CAL were documented, with:
a proximal right coronary artery Z-score of 6.02; left
main coronary Z-score of 5.72; and left anterior de-
scending Z-score of 5.78. Coronary artery Z-scores are
commonly used for decisions in KD management and
decisions on treatment, even if Z-scores show variations
based on the Z-scores formula used for larger coronary
artery dimensions [5]. However, the Z-score value for
CAL is useful for the follow-up of a patient and for test-
ing the response to treatment.
The child was promptly treated with IVIG at the dos-
age of 2 g/kg plus acetylsalicylic acid (ASA) at the dosage
of 5 mg/kg per day. Despite treatment, a further echo-
cardiographic evaluation showed worsening of CAL:
proximal right coronary artery Z-score of 5.93; left main
coronary Z-score of 5.63; and left anterior descending
Z-score of 5.39, which showed a saccular aneurysm of
2.9 mm of diameter (Z-score of 5.08).
A laboratory test did not show inflammation, but the
girl was treated with three bolus doses of intravenously
administered methylprednisolone at 30 mg/kg per dose.
The Z-score of CAL did not change. Informed consent
by parents was obtained, and our patient was treated
with anakinra at the dosage of 4 mg/kg per day. She
showed a progressive improvement of CAL and after
25 days of anti-IL-1 treatment, her proximal right cor-
onary artery Z-score was 0.93, left main coronary
Z-score 4.02, and left anterior descending Z-score
2.93. Treatment was continued for 2 months, at which
point Z-scores normalized (see Table 1).
The first diagnosis in this patient was a
parvovirus-related infection, which explained the
clinical manifestations and the clinical course of the
disease. The diagnosis of KD was reached late; a con-
trol echocardiogram showed CAL. Mild CAL are de-
scribed in systemic juvenile arthritis, in febrile
diseases, and in infectious diseases such as Mediterra-
nean spotted fever [6]. Aneurysms, conversely, are
typical of KD.
IVIG did not arrest the worsening of CAL, which were
stabilized after three doses of methylprednisolone. How-
ever, our patient received IVIG 26 days after the fever
started and this delay can explain the poor response. In
fact, a delay in IVIG infusion is recognized as a risk fac-
tor for non-response to first-line treatment, as demon-
strated in our population [6, 7].
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Case number 2
A 7-year-old Caucasian boy, the brother of Case number
1, presented fever (38 °C) and vomiting at the same time
as his sister, which spontaneously resolved after 4 days.
Four days later, he again had fever, abdominal pain,
tachycardia, and tachypnea. He was admitted to our car-
diologic unit. He showed pallor, tachypnea, stasis at the
pulmonary bases, tachycardia (180 beats/minute), gallop
rhythm, hypotension, and secondary anuria hepatomeg-
aly with pain at palpation. Hematological tests evidenced:
leukocytes of 24,680/mm3 with neutrophils of 19,744/
mm3, lymphocytes of 3430/mm3, and monocytes of 960/
mm3; hemoglobin, 10.4 g/dl; platelets, 632,000/mm3; CRP,
0.24mg/dl; aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and gamma-glutamyltransferase
(gamma-GT) in the normal range; creatine phosphokinase
(CPK), 773mg/dl; creatinine, 0.77mg/dl; and blood urea
nitrogen (BUN), 111mg/dl. He had elevated myocardial
necrotic enzymes (c-troponin T, 91.4 ng/l) and pro-brain
natriuretic peptide (BNP) > 70,000.
An echocardiogram revealed that the left ventricle had
a normal diameter (telediastolic diameter, 40 mm;
Z-score, 0.37) and generalized hypokinesia, with a severe
reduction of the ejection fraction (EF) (20–25%); the left
atrium was dilated (diameter, 35 mm; Z-score, 3.3) and
the mitral valve had a moderate insufficiency. The right
ventricle had normal dimension; the tricuspid valve
showed a moderate insufficiency. His suprahepatic veins
were dilated. No pulmonary hypertension was
documented. He received dopamine (5 gamma/kg per
minute), dobutamine (7 gamma/kg per minute), fur-
osemide (1 mg/kg) plus steroids (2 mg/kg). Clinical signs,
echocardiographic parameters, and plasmatic enzymes
showed a progressive but slow improvement. Sixteen
days later, his EF was 45%; however, a persistent septal
hypokinesia was documented. He continued to receive
treatment with furosemide and enalapril. Specific sero-
logical tests were performed to exclude Epstein–Barr
virus (for the skin rash, associated with fever and hepatic
cholangitis) [8] and coxsackie virus infection (for fever
and myocarditis) [9]. A nasal swab for influenza and
parainfluenza virus was negative. However, the index
case of the sister suggested we should run a serology test
for anti-parvovirus, and we found increased IgM
anti-parvovirus with low IgG.
A cardiologic follow-up revealed: a further EF improve-
ment (50%); left ventricle was 38mm (normal value: 32.7–
45.5); Z-score, 0.15. His right atrium and ventricle were in
the normal range for diameters and kinesis.
Discussion and conclusions
In the international literature cases of siblings simultan-
eously affected by KD are rare; however, familial recur-
rence of KD is documented [1]. In these cases, a genetic
background can be suspected. However, simultaneous
manifestations of the disease induce research for an in-
fective trigger, as documented in our patients. Parvovirus
can explain fever, rash, and anemia; these symptoms
were detected in our children in the first phase of their
illness, which was considered an infective disease. Fur-
thermore, pericarditis and/or myocarditis are possible
cardiac complications in parvovirus infection. For this
reason, Case number 2 was admitted to our cardiologic
unit and treated as a patient with parvovirus-induced
myocarditis.
CAL are not imputable to parvovirus infection but to
KD and the delay in the diagnosis in Case number 1 was
associated with the worsening of the vasculitis even
though our patient was treated with IVIG. After high
doses of steroids, no worsening of CAL was documented
by echography; however, the off-label treatment with
anakinra had a crucial role in reversing aneurysms.
In conclusion, we report on familial KD in two siblings
which had the same infectious trigger (parvovirus). The
brother was diagnosed as having post-viral myocarditis.
However, in view of the two different and simultaneous
evolutions, the girl showed KD with late CAL and aneu-
rysms, whereas the brother had Kawasaki shock
Table 1 Coronary artery lesions (Z-scores) substantial improvement during anakinra treatment
Days of
echocardiography
Proximal right coronary
artery mm
(normal values 0.82–2.20)
Proximal right
coronary artery
Z-score
Left main
coronary mm
(normal values 1.06–2.42)
Left main
coronary
Z-score
Left anterior
descending mm
(normal values 0.7–1.97)
Left anterior descending
Z-score
Before IVIG 3.5 5.93 3.6 5.63 3.1 5.40
Before anti-IL-1 3.5 5.93 3.6 5.63 3 5.39
T = 4 days after
anti-IL-1
3.5 5.93 3.6 5.63 3 5.39
T = 25 days after
anti-IL-1
1.8 0.93 3.05 4.02 2.22 2.93
T = 40 days after
anti-IL-1
1.8 0.93 2.9 3.46 2.2 2.77
T = 71 days after
anti-IL-1
1.6 0.27 2.5 2.19 1.8 1.43
IL interleukin, IVIG intravenous immunoglobulin
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syndrome with myocardial dysfunction. Viral illnesses
are well-documented triggers of KD; however, in these
cases the rarity is in the simultaneous occurrence in two
siblings, albeit with different phenotypes. Furthermore,
both the children showed a severe cardiac involvement,
which, in part, could be explained by the parvovirus
tropism specific for myocardial tissue. Of note, the girl
had aneurysms which almost disappeared after anakinra
treatment, a therapy which has been recently shown to
be promising for this disease. The significant response to
anakinra (an off-label treatment in this condition) is in
fact supported by other reports [4, 10–12]; by contrast,
anti-tumor necrosis factor (TNF)-alfa drugs are effective
especially in the control of fever and inflammatory pa-
rameters [13].
In addition, the follow-up of KD needs to consider a
late evolution in CAL, especially in patients with atypical
KD; this circumstance may be a cause of misdiagnosis.
The brother was diagnosed and treated as having myo-
carditis secondary to parvovirus infection. It is well
known, in fact, that parvovirus can elicit myocardial dys-
function with reduced EF, secondary to myocarditis.
However, the case of the sister highlighted that the pos-
sible correct diagnosis in the boy was Kawasaki shock
syndrome induced by a viral trigger [14].
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